Idiopathic Reactive Hypoglycaemia and Treatment With Fructo-Oligosaccharide
Primary Purpose
Hypoglycemia
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
FOS
Sponsored by
About this trial
This is an interventional treatment trial for Hypoglycemia focused on measuring Reactive hypoglycaemia, Fiber, Prevalence, Randomised controlled trial, Idiopathic reactive hypoglycemia
Eligibility Criteria
Inclusion Criteria:
- Ideopathic reactive hypoglycaemia defined as 1h or 2h glucose valued during OGTT < 3.9 mmol/l or 1h or 2h glucose values during OGTT < fasting glucose
Exclusion Criteria:
- Diabetes mellitus, impaired glucose tolerance, other reason for reactive hypoglycaemia than ideopacy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
1: FOS
2: Control
Arm Description
Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
Outcomes
Primary Outcome Measures
Oligofructose, ingested along with a meal, contributes to a postponed increase in blood glucose and stabilizes the glucose metabolism.
Secondary Outcome Measures
Impact of FOS on 24-hours interstitial glucose AUC
With FOS after 2 weeks there will be proportionate less study participants qualified for IRH diagnosis after 3 and 4 hours OGTT
FOS for 2 weeks alteres lipid values (total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol).
Fos for 2 weeks alteres fasting serum insulin and fasting glucagon
Full Information
NCT ID
NCT00802971
First Posted
December 3, 2008
Last Updated
November 16, 2009
Sponsor
Asker & Baerum Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00802971
Brief Title
Idiopathic Reactive Hypoglycaemia and Treatment With Fructo-Oligosaccharide
Official Title
Prevalence of Idiopathic Reactive Hypoglycaemia and Impact of Fructo-Oligosaccharide Supplementation on Blood Glucose Variability
Study Type
Interventional
2. Study Status
Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
December 2008 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
June 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Asker & Baerum Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Idiopathic reactive hypoglycemia (IRH) describes a condition where recurrent episodes of symptomatic hypoglycemia occurs one to four hours after a meal, usually following meals rich in carbohydrates. Differential diagnoses to be excluded include those caused by isulinomas or bariatric surgery (dumping syndrome), or iatrogenic induced hypoglycaemia.
The prevalence of IRH is not fully known. A British trial among 1136 random chosen women aged 17-50, reported that 37.9% experienced symptomatic hypoglycemia four times every month (mean value). However, not all reported symptoms attributed to a low blood glucose (BG) correlates with measured low levels of BG and a "true" hypoglycaemic episode, i.e., as defined by American Diabetes Association (ADA) when plasma BG value is < 3,9 mmol/l with or without accompanying symptoms. This was underscored in three studies from England, Canada and Denmark, in whom all reported hypoglycaemic symptoms, but in whom accompanying plasma glucose values < 3,3 mmol/l during hypoglycaemic symptoms only occurred in 23, 47 and 0% of the study subjects, respectively. The majority of those with symptoms related to IRH hence are having these symptoms without being classified as hypoglycemic according to conventional interpretations. However, a new (2005) ADA definition; relative hypoglycemia, also comprise these symptomatic cases of hypoglycemia following a plasma glucose > 3,9 mmol/l.
Hormonal and cerebral mechanisms tightly control the complex interplay of mechanisms involved in regulating BG concentration. Explanations for IRH are centralized around increased insulin secretion/sensitivity and/or down regulated transcription of glucagon receptor or reduced glucagons sensitivity- and secretion. Others assess an overabundance of adrenaline and cortisol, witch is excreted at the nadir of the BS curve (venous plasma glucose between 3.6 and 3.9). The latter event, during which typical symptoms is characterized of anxiety, fatigue, irritability, palpitations, nervousness, tachycardia, tremor and sweat.
Today, treatment is limited to dietary recommendations of eating frequent meals of moderate size, reasonably high in protein, and with a low glycaemic load. These advices keep cerebral glucose concentration stable and prohibit neuroglycopenic symptoms like hunger, dizziness, tingling, blurred vision, difficulty in thinking, and faintness. Pharmacologic attempts in treating IRH involves diazoxide, metformin, α-glucosidase inhibitor, glitazones and somatostatin, however, none of these medications are specifically indicated for the condition.
Fiber is a class of carbohydrate resistant to hydrolytic digestion in the upper bowel but fermented in the colon by bacterially produced enzymes. It makes the rate of ventricular emptying increase and prolongs the bowel transit time; thus having a minimal impact on BG values. Inulin and oligofructose are composed of polymers of oligofructose having characteristic features different from other fibers because of their physiological and biochemical attributes. Found in a variety of edible fruit and vegetables, their fermentation produces short-chain fatty acids that acidify the colonic content. This stimulates selectively the growth of beneficial and potentially health-promoting bifidobacteria and reduces potential harmful colon bacteria. Acting as prebiotica, oligofructose induces changes in the colonic epithelium and in miscellaneous colonic functions, inter alia, enhances calcium and magnesium absorption, modulates endocrine as well as immune functions and affects the metabolism of lipids positively. The latter, being at a systemic level, may contribute to modulating lipogenesis and reducing triglyceridemia by partially impairing hepatic cholesterol synthesis.
FOS has not yet been investigated thoroughly as a possible stabilizer of blood glucose. However, several non-oligofructose studies, using a high-fiber diet, indicates reduced pre-prandial BG values, less hypoglycemic cases, glukosuri, total cholesterol, triglycerides, VLDL cholesterol and area under the curve (AUC) in a 24 hours measurement (every 2 hour) of BG and insulin concentration.
Clinical evaluation of safety of inulin and oligofruktose as dietary fiber has reported 20 g/day of oligofructose to be well tolerated. The various GI side effects identified include abdominal pain and bloating, flatulence and osmotic diarrhea.
Despite the fact that fiber intake is proven inversely related to hypoglycemic events, possible benefits of daily FOS-supplementation have not yet been investigated systematically in persons suffering of IRH. Given the estimated high prevalence of IRH it is in our aim to:
Study the prevalence and characteristics of subjects with IRH in a relevant Norwegian study population of 414 study participants.
Evaluating the effect of FOS supplementation on blood glucose variability.
Detailed Description
See above
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoglycemia
Keywords
Reactive hypoglycaemia, Fiber, Prevalence, Randomised controlled trial, Idiopathic reactive hypoglycemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1: FOS
Arm Type
Experimental
Arm Description
Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
Arm Title
2: Control
Arm Type
No Intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
FOS
Intervention Description
Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
Primary Outcome Measure Information:
Title
Oligofructose, ingested along with a meal, contributes to a postponed increase in blood glucose and stabilizes the glucose metabolism.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Impact of FOS on 24-hours interstitial glucose AUC
Time Frame
4 weeks
Title
With FOS after 2 weeks there will be proportionate less study participants qualified for IRH diagnosis after 3 and 4 hours OGTT
Time Frame
4 weeks
Title
FOS for 2 weeks alteres lipid values (total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol).
Time Frame
4 weeks
Title
Fos for 2 weeks alteres fasting serum insulin and fasting glucagon
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ideopathic reactive hypoglycaemia defined as 1h or 2h glucose valued during OGTT < 3.9 mmol/l or 1h or 2h glucose values during OGTT < fasting glucose
Exclusion Criteria:
Diabetes mellitus, impaired glucose tolerance, other reason for reactive hypoglycaemia than ideopacy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Odd Erik Johansen, MD, PhD
Organizational Affiliation
Asker and Baerum Hospital
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
Idiopathic Reactive Hypoglycaemia and Treatment With Fructo-Oligosaccharide
We'll reach out to this number within 24 hrs